[go: up one dir, main page]

SG10201407936XA - Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) - Google Patents

Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Info

Publication number
SG10201407936XA
SG10201407936XA SG10201407936XA SG10201407936XA SG10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA
Authority
SG
Singapore
Prior art keywords
treatment
sle
antibodies
lupus erythematosus
systemic lupus
Prior art date
Application number
SG10201407936XA
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Röttgen
Benjamin Daelken
André Engling
Chantal Zuber
Niklas Czeloth
Andrea Wartenberg-Demand
Marcus Gutscher
Judith Wessels-Kranz
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of SG10201407936XA publication Critical patent/SG10201407936XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

41 HUMANIZED ANTI-IL-10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL- 10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibodyor fragment thereof. Nosuitabledrawing
SG10201407936XA 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) SG10201407936XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
SG10201407936XA true SG10201407936XA (en) 2015-01-29

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Country Status (17)

Country Link
US (4) US8852871B2 (en)
EP (2) EP2470209B1 (en)
JP (2) JP2013511994A (en)
KR (2) KR101802260B1 (en)
CN (2) CN102811736B (en)
AU (2) AU2010323037B2 (en)
BR (2) BR112012012912A2 (en)
CA (2) CA2782007C (en)
CO (1) CO6561779A2 (en)
CR (2) CR20120359A (en)
IL (2) IL219955A (en)
MX (2) MX343228B (en)
NZ (2) NZ600899A (en)
RU (2) RU2581812C2 (en)
SG (2) SG10201407935YA (en)
WO (2) WO2011064399A1 (en)
ZA (1) ZA201204843B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343228B (en) * 2009-11-30 2016-10-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle).
RU2679889C2 (en) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Methods of using interleukin-10 for treating diseases and disorders
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (en) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and conditions
EP3105251A4 (en) * 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
CN107430123B (en) * 2014-11-28 2020-04-14 通用电气健康护理生物科学股份公司 Methods for detecting analyte-ligand binding on sensor surfaces
CA2970759A1 (en) * 2014-12-15 2016-06-23 Morphosys Ag Antibodies for il-17c
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7121496B2 (en) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド Pegylated interleukin-10 for use in cancer therapy
JP7053453B2 (en) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド How to use interleukin 10 to treat diseases and disorders
SG11201804259UA (en) 2015-12-04 2018-06-28 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag Combination of anti-il10 and anti-pd1 antibodies in cancer treatment
AR114112A1 (en) * 2018-02-15 2020-07-22 Seattle Genetics Inc GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
AU2021383537A1 (en) 2020-11-18 2023-06-29 Astrazeneca Ab Steroid sparing
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Kits and composition methods for characterizing the anti-inflammatory response of a product
KR20240114801A (en) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Antibody specifically binding to IL-10 receptor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0567586B1 (en) * 1991-01-16 1995-07-12 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DK0600970T3 (en) 1991-08-06 2000-05-29 Schering Corp Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen-induced toxicity
DE4425115A1 (en) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
DE19529026C2 (en) 1995-07-28 1997-06-19 Robert Sabat Monoclonal antibodies against human interleukin-10
CN103833854B (en) * 2002-12-16 2017-12-12 健泰科生物技术公司 Immunoglobulin variants and application thereof
AR046833A1 (en) 2003-11-10 2005-12-28 Schering Corp ANTI-INTERLEUQUINA ANTIBODIES-10
HUE037489T2 (en) * 2007-08-29 2018-08-28 Sanofi Sa Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX343228B (en) * 2009-11-30 2016-10-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle).

Also Published As

Publication number Publication date
RU2012127381A (en) 2014-01-10
CN102711829A (en) 2012-10-03
US20120321617A1 (en) 2012-12-20
AU2010323037A1 (en) 2012-07-19
US8852871B2 (en) 2014-10-07
RU2587622C2 (en) 2016-06-20
AU2010323036B2 (en) 2015-01-29
RU2581812C2 (en) 2016-04-20
US20150218270A1 (en) 2015-08-06
WO2011064398A1 (en) 2011-06-03
IL219955A0 (en) 2012-07-31
KR20120103664A (en) 2012-09-19
MX350206B (en) 2017-08-28
JP2013511995A (en) 2013-04-11
CA2782007A1 (en) 2011-06-03
NZ600894A (en) 2014-09-26
CN102811736A (en) 2012-12-05
EP2470209A1 (en) 2012-07-04
KR101802261B1 (en) 2017-11-28
IL219955A (en) 2016-08-31
CA2782004A1 (en) 2011-06-03
BR112012012917A2 (en) 2016-10-25
US8956607B2 (en) 2015-02-17
CA2782007C (en) 2018-07-24
WO2011064399A1 (en) 2011-06-03
CN102711829B (en) 2016-03-16
US9540436B2 (en) 2017-01-10
US9605066B2 (en) 2017-03-28
MX2012006198A (en) 2012-06-19
CO6561779A2 (en) 2012-11-15
SG10201407935YA (en) 2015-01-29
CN102811736B (en) 2016-01-20
MX343228B (en) 2016-10-26
CR20120358A (en) 2013-01-23
MX2012006197A (en) 2012-06-19
JP6005519B2 (en) 2016-10-12
BR112012012912A2 (en) 2016-10-25
JP2013511994A (en) 2013-04-11
AU2010323037B2 (en) 2015-01-29
RU2012127380A (en) 2014-01-10
NZ600899A (en) 2014-09-26
KR20120115289A (en) 2012-10-17
IL219954A0 (en) 2012-07-31
ZA201204843B (en) 2020-02-26
AU2010323036A1 (en) 2012-07-19
KR101802260B1 (en) 2017-11-28
CR20120359A (en) 2013-01-25
US20120321618A1 (en) 2012-12-20
US20150064179A1 (en) 2015-03-05
IL219954A (en) 2016-10-31
EP2470209B1 (en) 2020-01-01
EP2470208A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
SG10201407936XA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
NZ607969A (en) Cd33 binding agents
MX2019014658A (en) Humanized antibodies that recognize alpha-synuclein.
NZ594985A (en) Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
MX354243B (en) Antibody polypeptides that antagonize cd40.
MX2013009362A (en) Antibody against the csf-1r.
WO2015091914A3 (en) Caninized murine anti-canine pd-1 antibodies
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ724296A (en) Antibodies for treatment of cancer expressing claudin 6
MX362039B (en) Anti-il-23 antibodies.
MX2009012812A (en) Mutated parvovirus structural proteins as vaccines.
NZ593905A (en) Il-1 binding proteins
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012097238A3 (en) Il-27 antagonists for treating inflammatory diseases
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PH12013500616A1 (en) Antibody compositions and methods of use
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
SG10201901695RA (en) Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
HK1202070A1 (en) Vaccine for tumor immunotherapy
MX2013009529A (en) Treatment of fistulizing crohn's disease.
MX2012002829A (en) Producing an immune response for reducing the risk of developing brucellosis.
MX2015004892A (en) Methods and compositions relating to anti-il-21 receptor antibodies.
MX2019006676A (en) Anti-ccl2 antibodies for treatment of scleroderma.
HK40064737B (en) Methods for purifying antibodies